Starling Oncology Reports Q2 2026 Financial Results

What Happened
Starling Oncology, Inc. announced its financial results for the three months ended June 30, 2026 via a press release dated August 6, 2026. The company furnished that press release as Exhibit 99.1 to an 8-K (Item 2.02 reporting results of operations and financial condition).

Key Details

• Filing date: August 6, 2026; reporting period: three months ended June 30, 2026.
• The press release containing the quarterly results is furnished as Exhibit 99.1 to the Form 8-K.
• The 8-K also references the Inline XBRL cover page (Exhibit 104) for interactive data.
• The Item reported is 2.02 (Results of Operations and Financial Condition); Exhibit disclosure appears under Item 9.01.

Why It Matters
This 8-K contains the company’s most recent quarterly earnings and financial information; investors should review the furnished press release (Exhibit 99.1) for revenue, profit/loss, cash position, and any commentary on guidance or development progress. The filing signals the availability of updated quarterly results that can affect near-term valuation and investment decisions.